Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

An open-label rollover study to assess the long-term safety of ixazomib

View Full Paper
Ask AI
Bookmark
Share

Authors

DYDok Hyun YoonOBOliver BechterXPXuejun Peng

Discussion

Loading...

Member takes

Overview

Open-label rollover study investigates ixazomib safety and tolerability in multiple myeloma and lymphoma patients, suggesting it remains well-tolerated long-term.

Key Points

  • Overall safety profile of ixazomib remains favorable, with no evidence of cumulative toxic effects over long-term use.
  • Among 32 patients, 68.8% experienced treatment-emergent adverse events, with pneumonia and anemia being most common.
  • Patients were previously treated with ixazomib for multiple myeloma, amyloidosis, or lymphoma, and continued on the same dose during rollover.
  • Study results indicate ixazomib, both as monotherapy and in combination, is well tolerated without contributing increased risks of adverse events.

Cite This Study

Yoon et al. (2025) studied this question.

synapsesocial.com/papers/69362f744fa91c937236e276https://doi.org/10.1182/blood-2025-7547
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Real-world efficacy and safety of ixazomib maintenance therapy in Chinese patients with newly diagnosed multiple myeloma: A multicenter retrospective study2025
  2. 2Treatment outcomes in patients with newly diagnosed multiple myeloma receiving ixazomib as initial therapy: A retrospective, observational, real-world historical database analysis from China2025
  3. 3In-class transition from bortezomib to ixazomib-based regimens in transplant-ineligible patients with newly diagnosed multiple myeloma: A retrospective, observational, real-world study conducted in China2025
  4. 4Long term safety and long term disease control of oral ixazomib and short-course rituximab in untreated iNHL2025
  5. 5Transition to ixazomib-based maintenance following daratumumab-based induction for continuous therapy in newly diagnosed multiple myeloma2025